BME:ADL

Stock Analysis Report

Executive Summary

ADL Bionatur Solutions, S.A. operates in biotech and pharmaceutical industry in Spain.

Rewards

Earnings are forecast to grow 81.3% per year

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (€75M)



Snowflake Analysis

Reasonable growth potential with weak fundamentals.

Share Price & News

How has ADL Bionatur Solutions's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

9.8%

ADL

2.7%

ES Biotechs

1.1%

ES Market


1 Year Return

-8.2%

ADL

39.4%

ES Biotechs

9.4%

ES Market

Return vs Industry: ADL underperformed the Spanish Biotechs industry which returned 37.5% over the past year.

Return vs Market: ADL underperformed the Spanish Market which returned 9% over the past year.


Shareholder returns

ADLIndustryMarket
7 Day9.8%2.7%1.1%
30 Day-2.1%5.2%2.9%
90 Day-11.6%12.9%7.8%
1 Year-8.2%-8.2%40.8%39.4%13.2%9.4%
3 Yearn/a38.0%35.7%17.1%5.9%
5 Yearn/a72.3%69.2%11.5%-7.1%

Price Volatility Vs. Market

How volatile is ADL Bionatur Solutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ADL Bionatur Solutions undervalued compared to its fair value and its price relative to the market?

4.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ADL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ADL is unprofitable, so we can't compare its PE Ratio to the Spanish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADL is overvalued based on its PB Ratio (4.1x) compared to the ES Biotechs industry average (3.8x).


Next Steps

Future Growth

How is ADL Bionatur Solutions forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

81.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).

Earnings vs Market: ADL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ADL's is expected to become profitable in the next 3 years.

Revenue vs Market: ADL's revenue (14.9% per year) is forecast to grow faster than the Spanish market (4.6% per year).

High Growth Revenue: ADL's revenue (14.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ADL Bionatur Solutions performed over the past 5 years?

-21.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADL is currently unprofitable.

Growing Profit Margin: ADL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADL is unprofitable, and losses have increased over the past 5 years at a rate of -21.1% per year.

Accelerating Growth: Unable to compare ADL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: ADL has a negative Return on Equity (-61.31%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ADL Bionatur Solutions's financial position?


Financial Position Analysis

Short Term Liabilities: ADL's short term assets (€22.9M) do not cover its short term liabilities (€28.5M).

Long Term Liabilities: ADL's short term assets (€22.9M) do not cover its long term liabilities (€37.7M).


Debt to Equity History and Analysis

Debt Level: ADL's debt to equity ratio (193.4%) is considered high.

Reducing Debt: Insufficient data to determine if ADL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: ADL has a high level of physical assets or inventory.

Debt Coverage by Assets: ADL's debt is not covered by short term assets (assets are 0.7x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ADL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.7% each year


Next Steps

Dividend

What is ADL Bionatur Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.2%markettop25%5.3%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ADL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ADL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADL's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jaime Feced 0

0.08yrs

Tenure

0

Mr. Jaime Feced serves as Chief Executive Officer and Director of ADL Bionatur Solutions, S.A. since January 2020. Mr. Feced was Managing Director at the plant in León of ADL Bionatur Solutions since Janua ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

ADL Bionatur Solutions, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ADL Bionatur Solutions, S.A.
  • Ticker: ADL
  • Exchange: BME
  • Founded: 1954
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €75.131m
  • Shares outstanding: 39.34m
  • Website: https://www.adlbionatur.com

Number of Employees


Location

  • ADL Bionatur Solutions, S.A.
  • Av. del Desarrollo Tecnológico, 11
  • Jerez de la Frontera
  • Cádiz
  • Andalusia
  • 11591
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADLBME (Bolsas y Mercados Espanoles)YesSocial SharesESEURMay 2018
41BST (Boerse-Stuttgart)YesSocial SharesDEEURMay 2018

Biography

ADL Bionatur Solutions, S.A. operates in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is based in Cádiz, Spain. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 22:25
End of Day Share Price2020/02/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.